Join

Compare · DXCM vs PROF

DXCM vs PROF

Side-by-side comparison of DexCom Inc. (DXCM) and Profound Medical Corp. (PROF): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DXCM and PROF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $23.76B, about 112.4x PROF ($211.3M).
  • Over the past year, DXCM is down 13.5% and PROF is up 48.4% - PROF leads by 61.9 points.
  • Both names hit the wire about 4 times in the past 4 weeks.
  • DXCM has more recent analyst coverage (25 ratings vs 7 for PROF).
PerformanceDXCM-13.51%PROF+48.42%
2025-04-28+0.00%2026-04-24
MetricDXCMPROF
Company
DexCom Inc.
Profound Medical Corp.
Price
$61.55-1.84%
$7.05+4.60%
Market cap
$23.76B
$211.3M
1M return
-7.89%
+20.72%
1Y return
-13.51%
+48.42%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2005
News (4w)
4
4
Recent ratings
25
7
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

PROF

Profound Medical Corp.

Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Latest DXCM

Latest PROF